A Randomized, Double-Masked, Vehicle-Controlled, Single-Center Phase 1 Clinical Study Evaluating the Safety, Tolerability and Pharmacokinetics of 0.25%, 0.5% and 1.0% VVN461 Ophthalmic Solution
Latest Information Update: 04 Apr 2025
At a glance
- Drugs VVN 461 (Primary)
- Indications Uveitis
- Focus Adverse reactions
- Sponsors VivaVision Biotech
- 04 Apr 2025 New trial record